 - Tumor must express either gp100 for patients HLA-A2 or HLA-A3 or tyrosinase for patients HLA-A1 or HLA-A2 by immunohistochemistry. The tumor deposits to be examined will be the primary lesion for stage IIB patients, or the most recently resected metastatic disease in stage III or stage IV patients. If the most recently resected deposit is not available than material from prior resected tumor will be evaluated. 